---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275507799.md"
description: "Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities."
datetime: "2026-02-10T19:25:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275507799.md)
  - [en](https://longbridge.com/en/news/275507799.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275507799.md)
---

# 

Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [BUZZ-Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe](https://longbridge.com/en/news/282832865.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)